CAP2

Across TCGA pan-cancer cohorts, CAP2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CAP2 data layer compared with 26 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CAP2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated CAP2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, UCEC, and CCRCC are the cancer types where CAP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	All	0.764	0.384	.007	27	view →
UCEC	OS	Median	II,III,IV	0.590	1.000	.007	12	view →
CCRCC	OS	Median	III,IV	0.917	0.715	.030	3	view →
LUAD	OS	Quartile	All	0.854	0.384	.029	2	view →
HNSC	DFS	Tertile	III,IV	1.000	0.911	.042	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CAP2–PDAC (OS)

Open the PDAC breakdown →